#ACR21 #AbstrL20 A promising new player on the block. A single-arm study of 14 pts with sJIA-associated MAS, Emapalumab (anti-IFNγ) induced remission in all pts with median 25 days, neutralised CXCL9 and allowed rapid steroid reduction @RheumNow #ACRBest https://t.co/7tnaS5tPJ0 https://t.co/G1IoFxLQoX
Links:
Efficacy of Emapalumab, an Anti-IFNγ Antibody in Patients with Macrophage Activ…
https://bit.ly/3Hhil5J
09-11-2021